Associations - gefitinib

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR G719S	Non Small Cell Lung Cancer	EGFR G719S	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR G719C	Non Small Cell Lung Cancer	EGFR G719C	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
CDK4 amplification	Non Small Cell Lung Cancer	CDK4 amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
NKX2-1 amplification	Non Small Cell Lung Cancer	NKX2-1 amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
TP53 exon 4 mutation	Non Small Cell Lung Cancer	TP53 exon 4 mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
MYC amplification	Non Small Cell Lung Cancer	MYC amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
TP53 exon 5 mutation	Non Small Cell Lung Cancer	TP53 exon 5 mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
TP53 exon 8 mutation	Non Small Cell Lung Cancer	TP53 exon 8 mutation	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR amplification	Non Small Cell Lung Cancer	EGFR amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR overexpression	Non Small Cell Lung Cancer	EGFR overexpression	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR mutation + NOTCH1 mutation	Non Small Cell Lung Cancer	EGFR mutation + NOTCH1 mutation	Non Small Cell Lung Cancer	gefitinib Resistant: B - Late Trials gefitinib Resistant : B	gefitinib Resistant: B - Late Trials gefitinib Resistant : B
EGFR mutation + CREBBP mutation	Non Small Cell Lung Cancer	EGFR mutation + CREBBP mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B

gefitinib

Associations
(194)

Associations
(194)

gefitinib

Associations(194)

Associations(194)

Associations
(194)

Associations
(194)